Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. Receives Notice Regarding NYSE Amex Continued Listing Standards
Date:7/15/2010

DETROIT, July 15 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) announced that on July 12, 2010, NYSE Amex notified the Company that it was not in compliance with the requirement under its continued listing standards that its audit committee be comprised of three independent members. On July 9, 2010, the Company informed NYSE Amex of its non-compliance with Section 803(B)(2)(a) of NYSE Amex Company Guide following the resignation of Mr. Madhava Reddy as a director of the Company on July 6, 2010, leaving two independent directors on the Company's audit committee. Additionally, the Company notified NYSE Amex that it intends, in conformance with NYSE Amex rules, to add another independent director to the audit committee within 180 days of the resignation.  

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic pharmaceuticals to the nation's largest wholesalers, distributors, drugstore chains and managed care providers.

Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limitation, the words "believe" or "expect" and similar expressions are intended to identify forward-looking statements. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties are contained in the Corporation's filings with the Securities and Exchange Commission, including Part I, Item 1A of our most recent Form 10-K, and include but are not limited to: information of a preliminary nature that may be subject to adjustment, potentially not obtaining or delay in obtaining FDA approval for new products, governmental restrictions on the sale of certain products, development by competitors of new or superior products or less expensive products or new technology for the production of products, the entry into the market of new competitors, market and customer acceptance and demand for new pharmaceutical products, availability of raw materials, timing and success of product development and launches, dependence on few products generating majority of sales, product liability claims for which the Company may be inadequately insured, material litigation from product recalls, the purported class action lawsuits alleging federal securities laws violations, delays in returning the Company's products to market, including loss of market share, increased reserves against the FDA-seized inventory, and other risks identified in this report and from time to time in our periodic reports and registration statements. These forward-looking statements represent our judgment as of the date of this report. We disclaim, however, any intent or obligation to update our forward-looking statements.


'/>"/>
SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Caraco Pharmaceutical Laboratories, Ltd. Enters Into Consent Decree with FDA Providing Path to Resume Manufacturing Operations
2. Caraco Pharmaceutical Laboratories, Ltd. Closes Asset Purchase Agreement with Forest Laboratories, Inc. to Settle Lexapro(R) (escitalopram oxalate) ANDA Patent Litigation
3. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal Year 2010
4. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Opthalmic Solution
5. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Ophthalmic Solution
6. Caraco Pharmaceutical Laboratories, Ltd. Markets Nicardipine Hydrochloride Injection
7. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Eloxatin(R)
8. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Exelon® Capsules
9. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Optivar®
10. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
11. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... Respiratory Devices - Medical Devices Pipeline ... sector report, " Respiratory Devices - Medical Devices ... Respiratory Devices currently in pipeline stage. The ... with comparative analysis of the products at various ... involved in the pipeline product development. It also ...
(Date:2/8/2016)... -- Aesthetic Devices - Medical Devices Pipeline Assessment, 2015 ... Devices - Medical Devices Pipeline Assessment, 2015" provides an ... This report is prepared using data sourced ... team of industry experts. *Note: Certain sections in ... the availability and relevance of data in relation to ...
(Date:2/8/2016)... Ohio , Feb. 8, 2016 ... introduce the PW Series Solvent Recycling Systems, specifically ... offers full integration with new and existing vapor ... integration produces consistently-fresh solvent through continuous recycling and ... --> --> Precision ...
Breaking Medicine Technology:
(Date:2/8/2016)... , ... February 08, 2016 , ... ... IN metro area, has selected the latest beneficiary of their ongoing community enrichment ... to preventing bullying in area schools. Donations are now being accepted at: ...
(Date:2/8/2016)... Pekin, IL (PRWEB) , ... February 08, 2016 ... ... debilitating conditions that co-occur frequently. While a significant number of women and men ... PTSD, not the trauma itself, that best predicts the development of an eating ...
(Date:2/8/2016)... ... 08, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to a ... derived from a cluster of melanin when exposed to sunlight. Although most moles are ... lifetime of embarrassment. Historically, mole removal has involved a painful, often expensive ...
(Date:2/7/2016)... Clarkston, Metamora, Michigan (PRWEB) , ... February 07, ... ... correct pelvic organ prolapse with the latest techniques and the most minimally invasive ... for pelvic organ prolapse, particularly after menopause. Other risk factors include surgery to ...
(Date:2/6/2016)... San Rafael, CA (PRWEB) , ... February 06, 2016 , ... ... 2016 Youth Ultimate Coaching Conference (YUCC) . This event brings together top non-profit leaders, ... is “Gender Equity and Girls Ultimate”. Valerio Iani, Bay Area Disc Program Director of ...
Breaking Medicine News(10 mins):